Together we will beat cancer

Donate

Hormone therapy gets green light for advanced prostate cancer

Adults in England with advanced hormone-sensitive prostate cancer that’s spread to other parts of the body will now have a new treatment option.

Read More

New hormone treatment for advanced prostate cancer made available in England

Hormone treatment enzalutamide will now be offered as an alternative combined treatment option for some adults with prostate cancer on the NHS in England.

Read More

Prostate cancer hormone therapy not recommended for NHS in England

A hormone therapy has been rejected for some adults with newly-diagnosed, advanced prostate cancer.

Read More

Hormone therapy now available for newly diagnosed prostate cancer in Scotland 

A hormone therapy has been approved for NHS use in Scotland for some people with newly diagnosed, advanced prostate cancer for the first time.  

Read More

Precision drug combo boosts survival in younger women with advanced breast cancer

Combining a targeted drug with hormone therapy extended the lives of pre-menopausal women with advanced breast cancer in a clinical trial.

Read More

Breast cancer relapse test can predict treatment benefits, study suggests

Using a test that measures gene activity could help to tailor treatment for some women with early stage breast cancer, new research suggests.

Read More

Advanced breast cancer drug combo approved for NHS in England

A new drug combo has been made available to some patients with advanced breast cancer on the NHS in England.

Read More

Prostate cancer drug given initial ‘no’ for NHS in England

The prostate cancer drug abiraterone has been provisionally rejected as a first-line treatment on the NHS in England.

Read More

Apalutamide delays spread of certain prostate cancers in trial

An experimental hormone therapy delays the spread of prostate cancer that has stopped responding to standard treatment, according to new clinical trial results.

Read More

Giving prostate cancer drug earlier extends lives of men whose disease has spread

Offering abiraterone (Zytiga) up-front with standard hormone treatment extends survival in men whose prostate cancer has spread.

Read More